Gufic Biosciences Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Gufic Biosciences Ltd filed with BSE on 21 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Gufic Biosciences reported Q1 FY27 revenue of INR260.8 crores versus INR226.9 crores in Q1 FY26, with EBITDA margin expanding to 18.09% from 14.6%. Management discussed progress at the Indore facility including depot and microsphere suite completion, a CMO partnership with Hetero for semaglutide, and a shift in international markets from a distributor-led to a front-end model. Management also addressed capacity utilization trends at Indore and reiterated a growth commitment for the company overall.
Numbers mentioned
Revenue from operations: INR260.8 crores (Q1 FY27)
p. 5
“Total revenue from operations in Q1 of '25-'26 was INR226.9 crores compared to Q1 of '26- '27, INR260.8 crores.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
EBITDA: INR47.2 crores (Q1 FY27)
p. 5
“The EBITDA for Q1 of '25-'26 was INR33.2 crores whereas the Q1 of '26-'27 is INR47.2 crores.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
EBITDA margin: 18.09% (Q1 FY27)
p. 5
“EBITDA margin in Q1 of '25-'26 was 14.6% whereas Q1 of '26-'27 is 18.09%.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
Profit before tax: INR30.1 crores (Q1 FY27)
p. 5
“Profit before tax in Q1 was INR16.3 crores whereas Q1 of '26-'27 is INR 30.1 crores.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
PBT margin: 11.56% (Q1 FY27)
p. 5
“The PBT margin in Q1 '25- '26 was 7.1%. In Q1 '26-'27 is 11.56%.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
Profit after tax: INR22.46 crores (Q1 FY27)
p. 5
“The profir after tax in Q1 of '25-'26 was INR12.1 crores. In Q1 '26-'27, it's INR22.46 crores.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
PAT margin: 8.61% (Q1 FY27)
p. 5
“The PAT margin in Q1 for '25-'26 was 5.3% whereas in Q1 '26-'27 was 8.61%.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
Revenue: INR252.1 crores (Q4 FY26)
p. 5
“The total revenue of Q4 of '25-'26 was INR252.1 crores whereas Q1 of '26-'27 is INR260.8 crores.”
Devkinandan Roonghta, page 5 of the filed PDF · View the filing
Fillers market size in India: around INR200 crores
p. 8
“So the fillers market in India is around INR200 crores.”
Pranav Choksi, page 8 of the filed PDF · View the filing
Expected revenue for FY27: around INR1100 crores (FY27)
p. 10
“Basically, if you see the expected revenue from our side for '26, '27 will in the rage of around INR1100 crores.”
Devkinandan Roonghta, page 10 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Company revenue growth — 15% to 20% · year-over-year
stated firmly by Pranav Choksi
p. 9
“But 15% to 20% is what we commit to you that would be a bare minimum.”
Pranav Choksi, page 9 of the filed PDF · View the filing
Indore capacity utilization — 40%, 45% · by year-end
stated as an aspiration by Pranav Choksi
p. 7
“And hopefully, like I said, we should end up the year on around 40%, 45% capacity utilization.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Filler product launch in India — December or January
stated conditionally by Pranav Choksi
p. 8
“And we hope at least December, if not December, maybe January, we should launch the filler in the Indian market.”
Pranav Choksi, page 8 of the filed PDF · View the filing
Maximum revenue potential without further capex — INR1,600 to INR1,800 crores
stated conditionally by Pranav Choksi
p. 11
“So answering your specific question that with no capex, keeping in mind the current product mix, keeping in the current realization per value, then we are looking at anything around INR1,600 to INR1,800 going forward.”
Pranav Choksi, page 11 of the filed PDF · View the filing
Operating leverage from Indore product mix — mid FY27-28
stated as an aspiration by Pranav Choksi
p. 13
“Yes, yes. You meant mid-2028 financial year Sorry, '27-'28 financials. Yes, you can say by mid- '27, '28 financial, the leverage should start kicking in, right?”
Pranav Choksi, page 13 of the filed PDF · View the filing
Toxin and filler market position in India — number 1 position · next 3 to 5 years
stated as an aspiration by Pranav Choksi
p. 8
“And we hope that with the help of these fillers, we can also not only strengthen our number 2 position, but very close to very close we can grab the number 1 position in terms of toxin and fillers in the next 3 to 5 years in India.”
Pranav Choksi, page 8 of the filed PDF · View the filing
Indore liquid line utilization — close to 80% capacity utilization · next 3 years
stated as an aspiration by Pranav Choksi
p. 12
“which would I hope in the next 3 years, that would come close to 80% capacity utilization.”
Pranav Choksi, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed the role is purely as a CMO partner to Hetero, with no front-end plans, and revenue traction was minimal in Q1.
Answered by Pranav Choksi
Asked by Bhavya: Is Gufic participating in GLP-1 with its own brand, and has third-party GLP manufacturing started contributing to revenue?
p. 5
“So Hetero got their permissions in May 2026. So our traction of their revenues was residual in the Q1.”
Pranav Choksi, page 5 of the filed PDF · View the filing
Management explained the move toward a front-end strategy in select markets to capture higher margins and build IP.
Answered by Pranav Choksi
Asked by Bhavya: How does the shift in the international model from distributor-led to IP-led benefit the company?
p. 6
“Wherever we have enough registration and economic of scale, we would like to deploy our own, I would say, field experts, which help us to get a better pricing.”
Pranav Choksi, page 6 of the filed PDF · View the filing
Management said they are awaiting feedback after submitting compliance data.
Answered by Pranav Choksi
Asked by Aarav: Is the company expecting an EU export certificate for Indore?
p. 7
“There were some compliance which we already have applied since the last 2-3 months and even the final data also has gone.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Management attributed the earlier margin drop to capitalization of Indore expenses and said current margin improvement reflects normal business progression.
Answered by Pranav Choksi
Asked by Aarav: Is 18% the new normal operating margin going forward?
p. 7
“But now with capacity utilization, with natural business progression as well as exports margin expansion along with domestic business also.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Management said revenue from fillers is expected post-December after registration, and GLP-1 traction should build from Q2/Q3 within the overall 15% growth guidance.
Answered by Pranav Choksi
Asked by Agam Shah: How will the Canada filler tie-up scale this year, and what growth can GLP-1 CMO contribute?
p. 8
“So we feel that the revenue would be captured maybe by post December because we have started the registration process in Q1 sorry, Q4 last year.”
Pranav Choksi, page 8 of the filed PDF · View the filing
Management said 15-20% is a floor, not a ceiling, due to product mix effects.
Answered by Pranav Choksi
Asked by Agam Shah: Are you being conservative with the 15% growth guidance?
p. 9
“I would say 15% to 20% is what we say we should grow year-on- year as overall, as a company, yes.”
Pranav Choksi, page 9 of the filed PDF · View the filing
Management said registration is starting in Southeast Asia and Africa, limited by current WHO Phase 1 facility capacity.
Answered by Pranav Choksi
Asked by Agam Shah: Is Botox (Stunnox) being launched in export markets?
p. 9
“So we are right now looking to register them only in the Southeast Asian markets, African markets to start off with.”
Pranav Choksi, page 9 of the filed PDF · View the filing
Management estimated combined peak revenue potential from Navsari and Indore facilities under the current product mix.
Answered by Pranav Choksi
Asked by Arvind Arora: What is the peak revenue possible from current capacity without further capex?
p. 11
“So totally, when I add both of them up, INR800 crores plus around 800 plus INR1,000 crores, it comes around INR1,600 crores to INR2,000 crores is the maximum capex I mean, maximum revenue, which is possible with current product basket and current legacy.”
Pranav Choksi, page 11 of the filed PDF · View the filing
Management attributed much of the increase to converting contract staff at Indore and Navsari to payroll for consistency in quality and output.
Answered by Pranav Choksi
Asked by Ameya: What is driving the substantial employee addition seen in the annual report?
p. 12
“Those people have just been decided to be taken on board to ensure that consistency as well as the output, both in terms of quality management systems and as well as in terms of quantity is consistent.”
Pranav Choksi, page 12 of the filed PDF · View the filing
Management indicated leverage should begin appearing around mid FY27-28 financial year.
Answered by Pranav Choksi
Asked by Ameya: When might Indore start showing real operating leverage gains from an improved product mix?
p. 13
“Yes, you can say by mid- '27, '28 financial, the leverage should start kicking in, right?”
Pranav Choksi, page 13 of the filed PDF · View the filing
Risks flagged
Indore export growth is constrained pending EU certification
p. 7
“Margin expansion using the Indore facility would, of course, come once we have what we call our EU in place.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Botulinum toxin export expansion limited by current facility capacity
p. 9
“But the limitation would be our facility. Our current facility is only WHO Phase 1 with limited capacity.”
Pranav Choksi, page 9 of the filed PDF · View the filing
GLP-1 plant faced temporary shutdowns affecting output
p. 8
“In the Q1 also, we had a 10- to 15-day plant shutdown because we were introducing a new machine, assuming that in March, Hetero would get the permission.”
Pranav Choksi, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.